The diagnostic algorithm for most cancers includes the assessment of a tissue specimen by a surgical pathologist, but if specimen provenance is uncertain, the diagnostic and therapeutic process carries significant risk to the patient. Over the last decade, short tandem repeat (STR) analysis has emerged as a DNA-based method with clinical applicability for specimen identity testing (also known as specimen provenance testing). Although the clinical utility of identity testing using STR-based analysis has been demonstrated in many studies, its economic value has not been established. Methods: We developed a decision-analytic model of the application of STR-based provenance testing of transrectal prostate biopsy specimens obtained as part of routine clinical care to rule out the presence of adenocarcinoma of the prostate, as compared with no STR-based testing. Using parameter values drawn from the published literature, the cost-effectiveness of STRbased testing was quantified by calculating the incremental costeffectiveness ratio per quality-adjusted life-year gained. Results: In comparison to the current standard practice of no identity testing, identity testing by STR-based analysis has an incremental cost-effectiveness ratio of $65,570 per quality-adjusted life-year gained at a testing cost of $618 per person. At a cost of $515 per person, identity testing would meet the conservative standard of $50,000 per quality-adjusted life-year. At a test cost of $290 per person, identity testing would be cost saving. Conclusion: Given the rapidly declining pricing of STR-based identity testing, it is likely that testing to confirm the identity of positive prostate biopsy samples will be a cost-effective method for preventing treatment errors stemming from misidentification. Studies to formally establish the frequency of specimen provenance errors in routine clinical practice would therefore seem justified.
Introduction
The diagnostic algorithm for most cancers includes the assessment of a tissue specimen by a surgical pathologist. The sample is taken from a patient with a known or suspected disease as part of a procedure in the office or surgical suite, labeled, and transported to the pathology lab for evaluation. The pathologist prepares the report, which then becomes the basis for treatment decisions. Underlying this series of events is the assumption that there is perfect continuity in the labeling and transport of the patient specimen that ensures that the specimen evaluated by the pathologist corresponds to the specimen obtained from the patient. If specimen provenance is uncertain, the diagnostic and therapeutic process carries significant risk to the patient [1, 2] .
There is an extensive literature on specimen identification errors (also known as specimen provenance errors, or SPEs), which can arise in the preanalytic (collection and processing), analytic, or postanalytic (reporting) stages of the specimen test cycle [3] [4] [5] [6] [7] [8] . Although recent reports have demonstrated that the application of new technologies in the clinical laboratory can decrease analytic SPEs [9 -11] , specimen mix-ups (which are a major class of identification errors) remain a significant high-risk concern in all surgical pathology laboratories [12, 13] . Despite more than a century of process improvement and technical innovation, the potential for specimen mix-ups, cross-contamination, floaters, or carryover artifacts has not been eliminated completely [3,5,14 -16] .
Over the last decade, short tandem repeat (STR) analysis has emerged as a DNA-based method with clinical applicability for specimen identity testing (also known as specimen provenance testing). The panel of STRs (also known as microsatellites) utilized in the testing is based on the Combined DNA Index System loci originally selected by the Federal Bureau of Investigation of the United States [17] . The Combined DNA Index System loci feature extreme polyallelism and widespread distribution of the different alleles across different population groups, characteristics that provide STR-based testing with a very high power of discrimination for assigning specimen provenance in clinical settings. The clinical utility of STR-based testing using the Combined DNA Index System loci is enhanced by the ease of testing (commercial kits for analysis are available), the availability of technical resources to support test interpretation, and an extensive literature that has demonstrated clinical utility for the resolution of a wide variety of specimen labeling and identification issues [14, 16, 18] .
Although the clinical utility of STR-based analysis has been demonstrated in many studies, its economic value has not been established. Nearly 40% of men with an abnormal digital rectal exam result or an elevated prostate-specific antigen who undergo transrectal prostate biopsies to rule out adenocarcinoma have a positive biopsy result [19] . Given this high percentage of men with latent disease, the occurrence of a specimen switch could frequently result in a correct, albeit accidental, finding. In most cases, however, the result of an SPE for the patient would be unnecessary morbidity and mortality associated with treatment, including the potential for incontinence or impotence. Avoiding this iatrogenic harm is the benefit of STR-based analysis, but a rigorous economic evaluation to determine whether the benefit outweighs the cost of this test has not been performed.
We conducted an economic evaluation of the application of STR-based provenance testing, versus no testing, of transrectal prostate biopsy specimens obtained as part of routine clinical care to rule out the presence of adenocarcinoma of the prostate. The parameter values in our model were drawn from the published literature, and we conducted extensive sensitivity analyses to identify those factors most associated with the cost-effectiveness of STR-based provenance testing.
Methods
We constructed a decision analytic model to compare the costeffectiveness of identity testing to prevent SPEs for prostate cancer biopsies positive for cancer, versus the current practice of no identity testing. Parameters in this model included estimates of the SPE rate in surgical pathology, the percentage of men biopsied who are diagnosed with prostate cancer, the usage of prostate cancer treatments by age, and the prevalence of side effects from treatment. We also included estimates for the quality-of-life effects of different combinations of side effects from treatment. Estimates for costs of DNA testing, prostate cancer treatment, and treatment of side effects were applied to the model on the basis of expert opinion and Medicare allowable. Uncertainty in the model stemming from variability in the values of the parameters was tested by using one-way and two-way sensitivity analyses. Analysis was conducted from a payer perspective, while assuming that qualityadjusted life-year (QALY) has meaning to a third-party payer. Costs were estimated by using the Medicare allowable.
Modeling the costs and effectiveness of identity testing for prostate cancer biopsies
In Figure 1 we provide an illustration of the Markov model to evaluate the potential adverse outcomes of cancer treatment. The treatment for prostate cancer differs by age, and so the model was stratified by age, with individuals aging throughout the modeling process (and mortality risk adjusted accordingly). Individuals whose specimen is correctly labeled face the same risk and benefit in both arms of our model; therefore, their outcomes do not affect the incremental result and are not illustrated here. Similarly, individuals with a mislabeled specimen who have prostate cancer in spite of the mislabeled sample (i.e., a surreptitious "true positive") also face the same risk and benefit in both arms of the model; therefore, their outcomes are not illustrated and were not modeled.
We assume that genetic testing is 100% accurate; therefore, no one in the "Identity Test" branch faces iatrogenic harm due to misdiagnosis; however, these patients do face the cost of a second biopsy to correct the initial erroneous diagnosis. We make the assumption that this second biopsy is 100% accurate with no identification error. In the "No Test" arm, misclassified patients undergo treatment for their incorrectly diagnosed cancer, facing the potential for adverse outcomes of treatment.
A Markov model was constructed to estimate the cost and benefit of long-term outcomes of treatment. The Markov model is a mathematical method of representing an iterative process, in this context, the medical/surgical process faced by a patient following a positive finding by the biopsy. The Markov process consists of a Major complications from radical prostatectomy [24] 4.8 0 10 Minor complications from radical prostatectomy [24] 9.5 0 20 Surgical death following radical prostatectomy [25] 0.48 0.18 0.59 Acute side effects (%) [21, 24] Brachytherapy series of cycles (in this context, the cycle is equal to 1 year) during which the patient faces consequences associated with the treatment of their disease, including the risk of adverse outcomes and additional costs [20] . In modeling side effects, we assumed that it is possible for side effects to either develop or resolve during the current or subsequent Markov cycle [21] . Therefore, for the first two cycles (years), a patient could move between treatment options. After this period, the patient remains in the final treatment state for the rest of his life and thus experiences the consequence of only that treatment for his remaining lifetime [22] . Table 1 , we present the values for the model parameters used in the model along with the ranges examined in sensitivity analyses, and the data source; most were taken from the 2009 report by the Institute for Clinical and Economic Review titled "Management options for low-risk prostate cancer: a report on comparative effectiveness and value" [24] . From this report, estimates of the short-and long-term side effects, the probabilities of complications following surgery, the costs of primary treatments, and the costs of treating side effects were determined.
Data and assumptions
The treatment decision following a diagnosis of prostate cancer is typically based on the presumed risk of progression and age of the patient [26] . As our relevant subgroup lacked a malignancy to progress, we assumed that treatment decisions would largely be based on the patient's age. The treatment decision by age was drawn from Cooperberg et al. [23] .
It is important to emphasize that we did not include in the base case any medical-legal costs based on the error of diagnosing and treating prostate cancer when, in fact, there was no cancer. We did, however, experiment with including legal costs in the model; the assumptions used in the experiment are that only individuals undergoing prostatectomy will sue and that any individual filing a lawsuit will win. In 2006, Sobel et al. [31] estimated that the average award in cases involving urology was $452,855, with a median of $185,000. We updated this average award by using data from Perrotti et al. [32] who estimated that the average indemnity payment increased 191% between 1985 and 2004, an average of about 3.2% per year, and that the average indemnity payment increased about 24% between 2000 and 2003 for an average of about 7.2% per year. Thus, to test the inclusion of legal costs in the model, the average and median award were used to construct a lognormal distribution, and the output of that lognormal distribution was updated by 4 years by using either a 3% inflation factor or a 7% inflation factor. The results from the model indicate that when using the 3% inflation factor, the cost of the no-test arm will equal the cost of the STR test arm if between 20% and 21% of the patients sue and that with the 7% inflation factor, the costs will be equal if 18% to 19% of the individuals file suit. This experiment indicates that legal costs would have a significant effect on the model if more concrete data could be obtained.
Estimating the utility of health states
To determine the effects of a treatment with an individual's health, a quantitative measure of quality of life must be used. In this study, we measured quality of life in terms of "utility." Utility is a preference-based measure that quantifies an individual's perception of the importance of functional limitation. The scale used to measure utility ranges from 0.0 to 1.0, with zero representing a health state comparable to death and 1.0 representing perfect health [33] . The utilities for each health state are then used to calculate the QALYs expected by living in that health state.
Utilities were used for three single health states and those complications resulting from active treatment, "erectile dysfunc- [29] 3.0 0.0 7.0 Probability positive biopsy (%) [30] 32.0 26.0 41.0 ED, erectile dysfunction; EBRT, electron beam radiation therapy; PADT, primary androgen disruption therapy; STR, short tandem repeat; WW/AS, watchful waiting with active surveillance.
tion," "urinary incontinence," and "bowel complications," along with all possible combinations of these health states. Utilities measuring the quality of life during primary androgen deprivation therapy and watchful waiting with active surveillance were also used in the construction of the model. All values for utility were taken from Stewart et al. [27] . Stewart et al. obtained standard gamble utilities for 19 health states from 162 subjects recruited as volunteers from the San Diego, CA, area, 52% of whom had been diagnosed with prostate cancer. Short-term disutility of treatment resulting from the invasiveness of surgery and radiation therapies was not included because the magnitude of these effects is unknown and omitting these effects provided a conservative estimate of the cost-effectiveness of identity testing.
Estimating the incremental cost-effectiveness
The incremental cost-effectiveness of one treatment compared with another is determined by dividing the incremental cost of a treatment by the incremental effectiveness (in the context of this study, effectiveness is estimated by QALYs). This is known as the incremental cost-effectiveness ratio (ICER) [34] . A treatment is considered cost-effective if the value that society places on a QALY is greater than the cost required to acquire the QALY via the proposed treatment. This value is based on society's "willingness to pay" (WTP), or the value that society places on a QALY. In this study, we used a WTP of $100,000 per QALY, regarded by many economists as the upper bound of WTP, as well as a conservative estimate of $50,000, as the thresholds for cost-effectiveness in sensitivity analyses [35] . The influence of model assumptions on the ICER was tested by using one-and two-way sensitivity analyses. The overall model stability was evaluated with probabilistic sensitivity analysis presented as a net benefits acceptability curve [36] . This was developed from the results of a second-order Monte Carlo simulation in which the model resampled 10,000 times to evaluate the influence of parameter uncertainty on the cost-effectiveness decision. As the costs and effects of treatment occur over a patient's remaining lifetime, future costs and benefits were discounted at a 3% rate [37] . The study time horizon was the patient's lifetime, and we took the payer perspective. All decision modeling and sensitivity analyses were performed by using TreeAge Pro 2009 (TreeAge Software, Inc., Williamsport, MA).
Results
The results of our analysis are shown in Table 2 . The strategies of "no identity test" and "identity test" are ranked in order of expected lifetime cost of identity testing and treatment related to misdiagnosis per person in the second column. The third column represents the incremental total lifetime cost of each strategy in comparison with the previous strategy. The fourth column is the effectiveness of each strategy measured in QALYs gained over the patient's remaining lifetime. The fifth column represents the expected incremental lifetime benefit of each strategy in the number of QALYs gained per person versus the other strategy. In this case, because "identity testing" prevents unnecessary treatment, there is a gain in QALYs lived by a simulated population. The sixth column represents the incremental cost-effectiveness of each strategy. This represents the cost at which one QALY can be "purchased" over those created from the previous strategy.
In comparison to the current practice of "no identity testing," "identity testing" has an ICER of $65,570 compared with the basecase scenario. Assuming a cost-effectiveness threshold between $50,000 and $100,000, "identity testing" would likely be considered a cost-effective method for preventing treatment errors stemming from the misidentification of prostate cancer biopsies [35] .
Sensitivity analysis
In one-way sensitivity analysis we found that the cost-effectiveness decision is sensitive to the rate of SPE in prostate cancer biopsies and the cost of the test. No other parameters with clinically relevant changes in assumed value resulted in a change of treatment decision, given a decision threshold between $50,000 and $100,000 per QALY gained.
We further evaluated the confidence that a decision-maker might have in the cost-effectiveness decision using two-way sensitivity analysis. We specifically examined the cost of DNA testing (per person) and the SPE rate. The results are shown in Figure 2 . This figure illustrates the combination of the cost of the DNA test and the SPE error rate for which testing would be cost-effective at a WTP of $50,000 and $100,000. In our illustration, points to the southeast of the WTP lines would represent combinations of accuracy and cost of DNA testing that would meet these standards of cost-effectiveness. In our base case, we used $618 per person for the cost of DNA testing and an SPE of 1.0% (this point is illustrated at the intersection of the vertical and horizontal lines of our graph). At a WTP of $100,000, identity testing would be considered to be cost-effective; however, at the more conservative standard of $50,000 per QALY typically used in other industrialized nations, identity testing would not be considered to be cost-effective. Figure 2 illustrates that if we assume the "true" SPE is 1.0 (represented by the blue vertical line), the cost of identify testing would need to drop below $515 per person to meet this standard of cost-effectiveness. Alternatively, if we assume that $618 per person represents the minimum that can be allowed for this test, the true SPE would have to be 1.15% to meet this standard of cost-effectiveness.
In Figure 3 we present the net benefit cost-acceptability curve for this evaluation. The price per test in this simulation is not varied, and therefore is fixed at $618 per person. At this price of testing, we see that the WTP must be more than $80,000 per QALY for there to be at least an 80% certainty that testing would be the most cost-effective option.
Discussion
In this economic evaluation of the cost-utility of STR-based testing to confirm the identity of positive prostate biopsy samples, we found an ICER of $65,570 per QALY gained. This would appear to be within the range normally accepted by health authorities in the United States but is above that normally accepted by payers in Europe or Canada ICER, incremental cost-effectiveness ratio; SPE, specimen provenance error; STR, short tandem repeat. * Calculated assuming an STR-based DNA testing cost of $618 and an SPE rate of 1% as in Table 1 . See Figure 2 for analysis of the impact on the ICER of changes in the cost of testing and SPE rate.
[ [33] [34] [35] [36] [37] [38] . To provide additional context to this estimate, consider that the ICER for mammography in women younger than 50 years is more than $200,000 per QALY gained, the ICER of using drug-eluting stents versus bare metal stents to avoid a major cardiac event is €18,311 ($25,536) [39] , and the use of fluorodeoxyglucose (18F)-PET for the diagnosis of lung cancer ranges from $16,000 to more than $200,000 per QALY depending on the pretest characteristics of the subject population [40] . Nonetheless, we have taken a very conservative approach. Because we did not have good evidence on these factors, we did not consider the medical-legal costs resulting from specimen mislabeling errors, or short-term disutility of treatment resulting from unnecessary surgery and radiation therapy. There is extensive literature on both the origin of specimen identification errors (i.e., specimen mislabeling errors) and the fre- For instance, if a policymaker were willing to pay $103,000 for a QALY, then "testing" provides the greatest net benefit for approximately 95% of the samples, while "no testing" provides the greatest net benefit to less than 5%.
quency with which the errors occur. SPEs that occur at the preanalytic stage are especially troublesome for pathologists because they may occur in the clinic or the operating room and are thus completely outside the control of the pathology laboratory [6 -8,11-13] . Specimen identification issues associated with deficiencies in specimen labeling, mismatches between the patient name on the container and the requisition slip, accessioning errors, and so on occur in about 6% of the accessioned cases on the basis of the College of American Pathologists Q-Probes study [13] . Specimen identification issues due to a presumably extraneous tissue contaminant in a surgical or cytology specimen occur in about 0.6% of the slides evaluated prospectively and 2.9% of the slides evaluated retrospectively with the specific intent to identify contaminants [15] ; of note, about 30% of the contaminants encountered prospectively are abnormal or neoplastic, and about 10% present some degree of diagnostic uncertainty. A limitation, however, of all published studies addressing SPEs is that none were designed to detect occult specimen identity errors although such occult errors are nonetheless known to exist as documented by many studies [14, 18, 16, 28, 41] . The demonstrated utility of STR-based testing to detect SPEs in the absence of any direct indication that a specimen switch may have occurred [16, 18, 41] highlights the clinical utility of the approach to detect specimen switches that cannot be captured by current laboratory protocols prospectively. While the magnitude of occult specimen switches is currently unknown, in Figure 2 we show that STRbased testing meets a cost-effectiveness standard of $100,000 per QALY at a wide range of combinations of clinically relevant test costs and misclassification rates. Nonetheless, it might be of interest to testmakers that our analyses found that at a cost of less than $515 per person, STR-based identity testing would be considered to be cost-effective in non-US jurisdictions and at a cost of less than $290 per person, STR testing would be cost saving. Similarly, given that the true SPE rate among patients with a positive biopsy finding is unknown, it is important to note that at an SPE rate of 1.15%, identity testing would meet the European and Canadian standards of cost-effectiveness.
It is important to emphasize that standard clinical laboratory practice incorporates over 100 years of process improvements and technical procedures designed to eliminate specimen switches and that recent improvements including differential specimen inking, use of bar coding, and even implementation of radiofrequency identification tags have all been shown to reduce the frequency of detected laboratory SPEs [9 -11] . By definition, however, real-time laboratory processes cannot detect specimen identification errors that occur prior to the assignment of the identifier or that occur in the clinic or the operating room before the specimen is received by the pathology laboratory. Because the specimen identification errors in these categories are outside the control of the pathology laboratory, they cannot be addressed by pathology lab-based quality assurance procedures [3] [4] [5] [6] [7] [8] . The power of STRbased specimen identification testing is that the approach makes it possible to address SPEs along the entire test cycle, regardless of whether the error is preanalytic (and outside the control of the pathology laboratory), analytic, or postanalytic. As such, STRbased specimen provenance testing is best viewed as an independent patient safety process. This process is initiated by the clinical physician in support of national patient safety goals and requirements [1, 2] because the testing is capable of addressing patient safety issues that extend from the clinic, the treatment room, or the operating room; through transport to the pathology laboratory; through specimen processing and analysis; and finally through test reporting steps. In this regard, it is noteworthy that insurance providers, including Medicare, pay for second (and even third) opinions of the diagnostic interpretation of patient specimens given the well-established occurrence of analytic and postanalytic errors that impact patient safety and clinical outcome [4, 42, 43] .
Conclusion
Our results demonstrate that STR-based testing is likely to produce a net benefit for society by reducing iatrogenic harm for patients. As a consequence, health policymakers should consider providing coverage for testing in patients undergoing prostate biopsy. While our findings are robust, demonstration that this result is real and not an artifact of our modeling process requires measurement of the frequency of occult SPEs in routine clinical practice.
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